Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinuvel’s Afamelanotide Receives Orphan Drug Designation From FDA
Clinuvel has announced that its photoprotective drug Afamelanotide has been granted an orphan drug designation (ODD) by the FDA for the management of solar urticaria (SU). This is
Clinuvel has announced that its photoprotective drug Afamelanotide has been granted an orphan drug designation (ODD) by the FDA for the management of solar urticaria (SU). This is
Bayer Technology Services (BTS) has collaborated with Lurgi to implement an operator training simulator (OTS) for a new Lurgi MTP process (methanol-to-propylene). At the core of the MTP
Merck & Co and Avecia have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck
BioDelivery Sciences has reported that the primary efficacy endpoint was achieved in the Phase 2 pain study assessing the efficacy and safety of Bema Buprenorphine. The positive results
Aurobindo Pharma has received the final approval for Cetirizine Hydrochloride syrup 1mg/ml from the FDA. The approval of Cetirizine Hydrochloride syrup is under the prescription drug product category.
Labopharm has initiated the regulatory approval process for its twice-daily Tramadol-Acetaminophen formulation in Europe under the decentralised procedure (DCP). According to DCP, Labopharm has submitted a marketing authorisation
YM BioSciences and Therapure Biopharma have entered into a service agreement, where by Therapure Biopharma will provide fill and finish services for Nimotuzumab, the humanized monoclonal antibody licensed
Cyanotech has launched new products for its Nutrex-Hawaii brand that target specific demographics and nutritional goals. The 100% vegetarian products are based on the company’s Hawaiian Spirulina Pacifica,
NovaBay Pharmaceuticals (NovaBay) has reported that its partner, Alcon has increased its on-going financial support of the company’s research and development efforts by more than $2m per year.
AlphaRx has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of